A Proteomic and Biochemical Study of HIV-1 Nucleoprotein Complexes

HIV-1 核蛋白复合物的蛋白质组学和生化研究

• 批准号: 7838226
• 负责人: MICHAEL A BELSHAN
• 金额: $ 37.33万
• 依托单位: CREIGHTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2015-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7838226
• 关键词: Affinity; Affinity Chromatography; Anti-Retroviral Agents; Antiviral Therapy; Area; Biochemical; Biological; Biological Assay; Biotinylation; Cell Nucleus; Cell physiology; Cells; Centrifugation; Combination Drug Therapy; Complement; Complex; Cyclophilin A; DNA; Detection; Development; Drug Delivery Systems; Drug resistance; Effectiveness; Event; Funding; G22P1 gene; Goals; HIV; HIV-1; Highly Active Antiretroviral Therapy; Individual; Infection; Investigation; Knowledge; Mass Spectrum Analysis; Measures; Methods; Morbidity - disease rate; Multi-Drug Resistance; Nuclear Import; Nucleoproteins; Play; Preparation; Prevalence; Probability; Protein Family; Proteins; Proteomics; Qualitative Methods; RNA Binding; Reporting; Repression; Research; Resistance; Reverse Transcription; Role; Sampling; System; Therapeutic; Toxic effect; Transcriptional Regulation; Viral; Viral Genome; Virion; Virus; Virus Replication; drug discovery; effective therapy; gag-pol Fusion Proteins; gain of function; in vivo; inhibitor/antagonist; innovation; knock-down; loss of function; member; mortality; novel; protein complex; public health relevance; resistant strain; small hairpin RNA; therapeutic target; therapy development; viral DNA; viral RNA

DESCRIPTION (provided by applicant): Drug resistant strains of human immunodeficiency virus type 1 (HIV-1) pose a significant challenge for effective long-term treatment of infection. One counter-measure against resistant strains of virus is treatment with therapeutics targeted to novel areas of HIV-1 replication. The long term goal of our research is to elucidate the assembly and transport of the HIV-1 preintegration complex (PIC) to aid in the development of novel antiretroviral therapeutics. The PIC facilitates the infection of cells with HIV-1 by targeting the viral DNA into the nuclei of cells after reverse transcription. Due to challenges in producing and purifying sufficient quantities of PICs there is limited understanding of their assembly, composition, and mechanism of nuclear import. Consequently, there are neither existing inhibitors of PICs nor any in development. The objective of this proposal is to identify and characterize novel cellular components of HIV-1 PICs. We have developed two complementary methods to reproducibly produce sufficient quantities of functional PICs for analysis by mass spectrometry. The feasibility of these approaches is demonstrated by the successful detection of known HIV-1 PIC components and the identification of several candidate proteins. At least one candidate thus far, LRP130, has been found to be critical for HIV-1 infection. These proposed studies will continue the investigation of role of LRP130 and other candidate proteins in HIV-1 replication using gain-of-function and loss-of-function assays. We will also identify additional PIC-associated cellular proteins using two innovative strategies. First, we will perform quantitative 2-D-DiGE proteomic analysis on PICs purified by velocity gradient centrifugation. Second, we will affinity purify HIV-1 protein complexes using a novel in vivo biotinylation method. Successful completion of these studies will identify new cellular co-factors critical for the early steps of HIV-1 replication, advance the understanding of PIC assembly and transport, and discover new targets for the development of antiviral therapies. The Specific Aims are: 1. To determine the role of identified candidate proteins in HIV-1 replication. 2. To identify additional cellular proteins associated with HIV-1 PICs during early replication. 3. To characterize new candidate proteins. PUBLIC HEALTH RELEVANCE: The ability of HIV-1 to rapidly evolve resistance to the components of highly active antiretroviral therapy poses a significant challenge for the successful long-term treatment of infected individuals. New drugs that target novel areas of HIV-1 replication have the greatest probability for continued repression of virus replication. The goal of this proposal is to identify and characterize candidate cellular proteins associated with HIV-1 preintegration complexes for the development of new antiretroviral therapeutics.

描述(由申请人提供)：人类免疫缺陷病毒1型(HIV-1)耐药株对有效的长期感染治疗构成了重大挑战。对抗耐药病毒株的一种对策是针对HIV-1复制的新领域进行治疗。我们研究的长期目标是阐明HIV-1前整合复合体(PIC)的组装和运输，以帮助开发新的抗逆转录病毒疗法。PIC通过反转录后将病毒DNA靶向细胞的细胞核，促进了HIV-1对细胞的感染。由于在生产和提纯足够数量的PIC方面存在挑战，人们对它们的组装、组成和核进口机制的了解有限。因此，既没有现有的PIC抑制物，也没有任何正在发展中的抑制物。这项提案的目的是识别和表征HIV-1 PIC的新细胞成分。我们已经开发了两种互补的方法来重复性地产生足够数量的功能图用于质谱分析。这些方法的可行性通过对已知的HIV-1 PIC组分的成功检测和几个候选蛋白的鉴定而得到证明。到目前为止，至少有一个候选基因LRP130被发现对HIV-1感染至关重要。这些拟议的研究将继续使用功能获得和功能丧失分析来研究LRP130和其他候选蛋白在HIV-1复制中的作用。我们还将使用两种创新策略识别更多与PIC相关的细胞蛋白。首先，我们将对速度梯度离心法纯化的PIC进行定量的2-D-DGE蛋白质组学分析。第二，我们将使用一种新的体内生物素化方法来亲和纯化HIV-1蛋白复合体。这些研究的成功完成将确定对HIV-1复制的早期步骤至关重要的新的细胞辅助因素，促进对PIC组装和运输的理解，并为抗病毒疗法的开发发现新的靶点。其具体目的是：1.确定已确定的候选蛋白在HIV-1复制中的作用。2.在早期复制过程中鉴定与HIV-1 PICS相关的其他细胞蛋白。3.鉴定新的候选蛋白。 与公共卫生的相关性：艾滋病毒-1对高效抗逆转录病毒疗法的成分迅速产生抵抗力的能力对成功地长期治疗感染者构成重大挑战。针对HIV-1复制的新领域的新药最有可能继续抑制病毒复制。这项建议的目标是确定和表征与HIV-1前整合复合体相关的候选细胞蛋白，以开发新的抗逆转录病毒疗法。